TearLab Corporation operates as an in-vitro diagnostic company in the United States. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease. The company’s system enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, which is a single-use microfluidic microchip; TearLab pen, which is a hand-held device that interfaces with the TearLab disposable; and TearLab reader, which is a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.

  • TearLab Announces Acquisition By Accelmed Partners And Related $25 Million Investment
    on May 11, 2020 at 11:00 am

    TearLab Corporation (OTCQB: TEAR), a leader in Ocular Surface Diagnostics, today announced it has entered into a definitive agreement pursuant to which Accelmed Partners II (AP-II) will acquire TearLab. In connection with the acquisition, AP-II has agreed to an investment of $25 million over two tranches that will occur in conjunction with the company delisting from the "over the counter" OTCQB market and TearLab and its senior secured lender, CR Group, has agreed to restructure the terms of the company's outstanding senior secured indebtedness. Post transaction, TearLab will be a private company and AP-II will be the controlling shareholder. Proceeds from the AP-II investment will be used to pay down a portion of TearLab's existing debt, and fund both organic and inorganic growth opportunities.

  • TearLab Corporation Confirms Merger Discussions
    on May 7, 2020 at 12:00 pm

    Any transaction would be subject to the approval of TearLab’s board of directors and stockholders, as well as other customary conditions contained in a definitive agreement. TearLab cautioned that no agreement has been reached. TearLab also noted that there cannot be any assurance that an agreement will be reached or, if an agreement is reached, that a transaction will be completed.

  • TearLab Resubmits 510(k) for U.S. FDA Clearance of the TearLab Discovery™ MMP-9 Test
    on April 22, 2020 at 8:05 pm

    The submission covers the TearLab Discovery™ Platform and its single-use, disposable Test Card measuring the inflammatory biomarker, matrix metalloproteinase 9 (MMP-9). TearLab Discovery™ will also be capable of performing the Company’s current FDA cleared tear osmolarity test.

  • Klinik Health Ventures Corp. Announces Qualifying Transaction
    on March 20, 2020 at 9:13 pm

    The LOI outlines the principal terms and conditions which will result in a reverse takeover of Klinik by NeuPath (the "Transaction"). Klinik is a Capital Pool Company and intends for the Transaction to constitute its Qualifying Transaction, as such terms are defined in the policies of the TSX Venture Exchange (the "TSXV").

  • TearLab Corporation Reports Fourth Quarter and Full Year 2019 Financial Results
    on March 5, 2020 at 9:05 pm

    ESCONDIDO, Calif., March 05, 2020 -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and.

  • TearLab Corporation Reports Third Quarter 2019 Financial Results
    on November 7, 2019 at 9:05 pm

    ESCONDIDO, Calif., Nov. 07, 2019 -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the third quarter.

[custom-facebook-feed id=TearLab ownaccesstoken=true pagetype=page seemoretext=’Expand’ ajax=true]

TearLab is proud to be a major sponsor of the Ocular Surface Disease Symposium. Join us September 22nd for a conversation with Donald Korb, OD on the 40th anniversary of his groundbreaking Meibomian Gland Dysfunction paper.

➡️ Register: https://www.neco.edu/ocular-surface-2020

TearLab delivers advanced and accurate measurement of #dryeye disease and provides objective insights to better inform your diagnosis and management of the ocular surface. Create practice efficiencies and reduce surgeon chair time.
➡️ https://www.tearlab.com

The TearLab Osmolarity System is the first objective and quantitative test for diagnosing and managing dry eye disease. Empower your #dryeye diagnosis and gain immediate insight into ocular surface health.
➡️ https://www.tearlab.com

TearLab is #hiring! We are growing and looking for talented Business Development Representatives to join our team. Learn more and apply here: https://app.trinethire.com/companies/32066-tearlab-corporation/jobs

TearLab is proud to be a major sponsor of the Ocular Surface Disease Symposium, a “Systematic Approach to Diagnosis and Treatment of Dry Eye Disease.” Join us August 25th at 6.30 ET. Each session is two hours of COPE approved education.

➡️ Register: http://events.r20.constantcontact.com/register/event?oeidk=a07eh8owf03ab9210db&llr=4d5izdfab

Load More...


What's Your Role?*



Company Description*



TearLab Corporation

9980 Huennekens Street
Suite 100
San Diego, CA 92121

+1 (858) 455-6006


September 2020

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account